Anavex Life Sciences Corp. (NASDAQ:AVXL – Get Free Report) saw a significant decrease in short interest in the month of September. As of September 30th, there was short interest totalling 17,590,000 shares, a decrease of 10.3% from the September 15th total of 19,610,000 shares. Based on an average daily volume of 903,000 shares, the short-interest ratio is presently 19.5 days.
Wall Street Analysts Forecast Growth
A number of research firms have issued reports on AVXL. EF Hutton Acquisition Co. I upgraded shares of Anavex Life Sciences to a “strong-buy” rating in a report on Monday, July 22nd. HC Wainwright restated a “buy” rating and issued a $40.00 price objective on shares of Anavex Life Sciences in a research note on Thursday, August 1st.
Get Our Latest Stock Report on Anavex Life Sciences
Institutional Investors Weigh In On Anavex Life Sciences
Anavex Life Sciences Stock Up 1.4 %
AVXL opened at $5.61 on Thursday. The firm has a market cap of $474.84 million, a price-to-earnings ratio of -11.05 and a beta of 0.61. Anavex Life Sciences has a 52 week low of $3.25 and a 52 week high of $10.45. The business’s 50 day moving average is $5.71 and its two-hundred day moving average is $4.94.
Anavex Life Sciences (NASDAQ:AVXL – Get Free Report) last released its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.01. During the same quarter in the previous year, the company posted ($0.14) earnings per share. Equities analysts expect that Anavex Life Sciences will post -0.55 EPS for the current fiscal year.
Anavex Life Sciences Company Profile
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.
See Also
- Five stocks we like better than Anavex Life Sciences
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- NuScale Rockets Higher on Amazon Deal: How High Can It Go?
- Airline Stocks – Top Airline Stocks to Buy Now
- Why Micron Could Rally All The Way Through Q4
- Best Aerospace Stocks Investing
- Should Warren Buffett’s Favorite Stock be Yours Too?
Receive News & Ratings for Anavex Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.